Y-mAbs Therapeutics, Inc. Quarterly Liabilities and Equity in USD from Q4 2017 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
Summary
Y-mAbs Therapeutics, Inc. quarterly Liabilities and Equity history and growth rate from Q4 2017 to Q3 2024.
  • Y-mAbs Therapeutics, Inc. Liabilities and Equity for the quarter ending September 30, 2024 was $121M, a 6.18% decline year-over-year.
Liabilities and Equity, Quarterly (USD)
Liabilities and Equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 $121M -$7.97M -6.18% Sep 30, 2024 10-Q 2024-11-08
Q2 2024 $144M +$11.6M +8.79% Jun 30, 2024 10-Q 2024-08-12
Q1 2024 $123M -$14.1M -10.3% Mar 31, 2024 10-Q 2024-05-07
Q4 2023 $128M -$13.6M -9.61% Dec 31, 2023 10-Q 2024-11-08
Q3 2023 $129M -$15M -10.4% Sep 30, 2023 10-Q 2023-11-13
Q2 2023 $132M -$32.8M -19.8% Jun 30, 2023 10-Q 2023-08-10
Q1 2023 $137M -$53.6M -28.1% Mar 31, 2023 10-Q 2023-05-08
Q4 2022 $141M -$71.3M -33.5% Dec 31, 2022 10-K 2024-02-29
Q3 2022 $144M -$96.1M -40% Sep 30, 2022 10-Q 2022-11-07
Q2 2022 $165M -$94.3M -36.3% Jun 30, 2022 10-Q 2022-08-08
Q1 2022 $191M -$83.9M -30.5% Mar 31, 2022 10-Q 2022-05-09
Q4 2021 $213M +$80.7M +61.1% Dec 31, 2021 10-K 2023-03-30
Q3 2021 $240M +$96.8M +67.6% Sep 30, 2021 10-Q 2021-11-04
Q2 2021 $259M +$92.2M +55.1% Jun 30, 2021 10-Q 2021-08-09
Q1 2021 $275M +$80.8M +41.7% Mar 31, 2021 10-Q 2021-05-06
Q4 2020 $132M -$84.3M -39% Dec 31, 2020 10-K 2022-03-01
Q3 2020 $143M +$39.5M +38.1% Sep 30, 2020 10-Q 2020-11-05
Q2 2020 $167M +$41.3M +32.8% Jun 30, 2020 10-Q 2020-08-06
Q1 2020 $194M +$54.1M +38.6% Mar 31, 2020 10-Q 2020-05-07
Q4 2019 $216M +$64.4M +42.4% Dec 31, 2019 10-K 2021-03-01
Q3 2019 $104M -$62.7M -37.7% Sep 30, 2019 10-Q 2019-11-13
Q2 2019 $126M Jun 30, 2019 10-Q 2019-08-14
Q1 2019 $140M Mar 31, 2019 10-Q 2019-05-10
Q4 2018 $152M +$59.8M +64.9% Dec 31, 2018 10-K 2020-03-12
Q3 2018 $166M Sep 30, 2018 10-Q 2018-11-13
Q4 2017 $92.1M Dec 31, 2017 10-K 2019-03-22
* An asterisk sign (*) next to the value indicates that the value is likely invalid.